PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback